BioStock: Abliva on the positive study results

Last week, Abliva announced positive safety and pharmacokinetic data from its phase Ia/b study with KL1333, as well as signals of efficacy in relevant clinical outcome measures in patients with primary mitochondrial diseases.BioStock reached out to the company CEO, Ellen Donnelly, for a comment.

Read the full interview with Ellen Donnelly at biostock.se:  

https://www.biostock.se/en/abliva-on-the-positive-study-results/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se